This review aims to provide a translational perspective on recent developments in heart failure with preserved ejection fraction (HFpEF), linking mechanistic insights to potential therapies. A key concept in this review is that HFpEF is a haemodynamic condition wherein the heart fails to keep up with the circulatory demands of the body, or does so at the expense of raised left ventricular filling pressures. We, therefore, propose that the 'final common pathway' for development of congestion, i.e. basic haemodynamic mechanisms of increased left ventricular end-diastolic pressure, left atrial hypertension, pulmonary venous congestion, and plasma volume expansion, represents important initial targets for therapy in HFpEF. Accordingly, we group this review into six mechanisms translating into potential therapies for HFpEF: beginning with three haemodynamic mechanisms (left atrial hypertension, pulmonary hypertension, and plasma volume expansion), and working backward to three potential molecular mechanisms [systemic microvascular inflammation, cardiometabolic functional abnormalities, and cellular (titin)/extracellular (fibrosis) structural abnormalities].
Treating symptoms and precipitating causes in heart failure with preserved ejection fraction: current management Symptomatic treatment of HFpEF is empiric and consists primarily of diuretics to reduce congestion, although the data to support even the use of diuretics are limited. Similarly, the data for rate control in patients with atrial fibrillation, which is highly prevalent in HFpEF, are limited. 6 Whether rhythm control would be of benefit in patients with
HFpEF and atrial fibrillation remains unclear. There is strong indirect evidence that treatment of hypertension can be beneficial in HFpEF prevention, although the data are less clear for reducing morbidity or mortality in patients with known HFpEF. In both the HYVET trial 7 and SPRINT trial, 8 patients with aggressive blood pressure lowering had significantly fewer HF hospitalizations compared with those with less aggressive blood pressure control. In patients with established HFpEF, blood pressure lowering must be balanced by the consideration that HFpEF patients have steep end-systolic pressure-volume relationships index > _1. 4 roughly equivalent to EF 40%) trial was a definitively neutral trial, there was a suggestion that perindopril was beneficial at the 1-year time point, after which many patients crossed over to open label ACE-inhibition. The Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial comparing spironolactone with placebo showed a non-significant 11% reduction in a combined primary endpoint of cardiovascular death, aborted cardiac arrest or HF hospitalization, but there was a significant reduction in HF hospitalizations overall. 13 When the data were unblinded, substantial regional variation was noted, with overall event rates being considerably lower in patients enrolled from Russia and the Republic of Georgia, compared with those enrolled in the USA, Canada, Argentina, and Brazil. 14 These data suggested that some patients enrolled in Russia and Georgia may not have had HF. Further investigation has suggested that many patients in these regions did not likely take the study drug, despite the fact that they had reported that they were. 15 It has been argued that without the contamination from patients who may not have had HF, TOPCAT would have been a positive trial and recent AHA/ACC guidelines have suggested that spironolactone may be considered in HFpEF for refractory patients. 16 More recent data suggest that HFpEF patients at the lower end of the 'preserved' EF spectrum (EF < 55%) might indeed benefit to a greater extent from RAAS inhibition than those at the higher end.
Heart failure with preserved ejection fraction: mechanisms to future therapies A key concept in this review is that HFpEF, like HFrEF, is a haemodynamic condition wherein the heart fails to keep up with the circulatory demands of the body, or does so at the expense of raised left ventricular filling pressures. We therefore propose that the 'final common pathway' for development of congestion, i.e. basic haemodynamic mechanisms of increased left ventricular end-diastolic pressure, left atrial hypertension, pulmonary venous congestion, and plasma volume expansion, represents important initial targets for therapy in HFpEF ( Figure 1 Figure 2 Mechanisms in heart failure with preserved ejection fraction. Six mechanisms are outlined in this review-three haemodynamic (orange) and three cellular/molecular (grey). Data for cardiometabolic abnormalities are largely from other animal models and heart failure with reduced ejection fraction, but hypothesized to be applicable to heart failure with preserved ejection fraction. Figure 1 Principles of managing heart failure with preserved ejection fraction and heart failure with reduced ejection fraction. AF, atrial fibrillation.
Heart failure with preserved ejection fraction . Left heart congestion/diastolic dysfunction/left atrial hypertension
Mechanism
Left ventricular diastolic dysfunction (abnormal active relaxation and increased passive stiffness) is a key defining feature of HFpEF. 1 The landmark invasive haemodynamic study by Zile et al. 17 showed that patients with 'diastolic heart failure' had more impaired relaxation and higher diastolic stiffness compared to healthy controls. This was confirmed in a large population-based study in which HFpEF was distinguished from age-and comorbidity (hypertension)-matched controls by the presence of more severe diastolic dysfunction and increased left atrial size. 18 The distinction from age-and comorbiditymatched controls is important since community-based elderly adults without HFpEF are known to have diastolic dysfunction. 19 Furthermore, left ventricular diastolic dysfunction predisposed to new-onset HFpEF in the Framingham Heart Study, 20 and blunted diastolic reserve function was demonstrable among patients with newly diagnosed HFpEF. 21 Arterial stiffening and abnormal pulsatile aortic loading during exercise also contribute to higher left ventricular filling pressures in HFpEF. 22 In the absence of mitral valve disease, left atrial pressure reflects left ventricular end-diastolic pressure, and left atrial remodelling is used as an index of left ventricular diastolic dysfunction. Left atrial enlargement and dysfunction, including blunted left atrial systolic reserve with exercise, distinguished HFpEF from hypertensive controls without HF. 23, 24 Furthermore, left atrial dysfunction was shown to be related to symptom onset, 25 exercise capacity, and outcomes in HFpEF. 26 31 The CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients (CHAMPION) trial was a prospective, single-blinded, randomized controlled clinical trial testing the hypothesis that haemodynamically guided HF management using a wireless pulmonary artery pressure recorder (CardioMEMS) decreased HF hospitalization. Among 119 patients with HFpEF (EF > _ 40%) in CHAMPION, a greater reduction in pulmonary pressures was associated with a 46% reduction in HF hospitalization over 6 months. 32 As a result, wireless monitoring of pulmonary artery pressure has received a Class IIb-B recommendation in HF in the most recent ESC HF Guidelines. More recent data obtained from general clinical use have suggested that similar results can be obtained in non-trial settings. 33 Pulmonary vascular disease and right ventricular dysfunction
Pulmonary hypertension (PH) frequently develops in patients with left ventricular HF, including those with preserved EF (HFpEF), and it has been reported to be present in 40-80% of patients. [34] [35] [36] Increased left ventricular filling pressure in HFpEF leads to pulmonary venous congestion and secondary pulmonary hypertension. In fact, pulmonary arterial pressure (PAP) is a marker of the severity and chronicity of pulmonary venous congestion/hypertension in HFpEF, and if present, PH is associated with more symptoms and a poorer outcome. 35 Pulmonary hypertension can be classified as pre-capillary (pulmonary capillary wedge pressure < _15 mmHg) or post-capillary (>15 mmHg), and in HFpEF most patients have isolated post-capillary PH (IpcPH), although overlaps (or combination) of the two conditions occur (combined pre-and post-capillary PH, CpcPH). 37, 38 The identification of HFpEF patients who have additional pre-capillary PH is important, since these patients may respond (better) to pulmonary vasodilator therapy, 39 and they generally have a poorer prognosis. 37 Right ventricular dysfunction appears to be present in approximately 30% of patients, depending on the criteria used. 34, 40, 41 The presence and severity of PH are strongly associated with the development of RV dysfunction, but beyond increased pulmonary pressure, RV-arterial uncoupling also plays an important role, further contributing to worse outcomes in HFpEF. 34, [40] [41] [42] In aggregate, these studies suggest that pulmonary vascular disease may be an important therapeutic target in HFpEF. 43 Furthermore, abnormalities in the lungs themselves, with altered pulmonary function and lowered diffusing capacity, have been shown to contribute to exercise intolerance and mortality in HFpEF. 44, 45 Reduced diffusing capacity in the lungs correlated with the extent of pulmonary vascular remodelling by quantitative histomorphometry in autopsy specimens from patients with HF. Of note, the severity of PH correlated most strongly with venous and small pulmonary vessel (rather than arterial) intimal thickening among patients with HF, similar to the pattern in primary pulmonary veno-occlusive disease, suggesting that pulmonary venous remodelling may be the prime target in patients with HF and PH. 46 
Therapy
Treatment directly aimed at PH, to reduce RV afterload thereby improving RV function in HFpEF, is a tantalizing concept but efforts so far have been disappointing. 41 Phosphodiesterase (PDE)-5 inhibitors are established drugs in patients with pulmonary (arterial) hypertension without HF(pEF). 47 The effects have also been studied in patients with HFpEF and PH, [48] [49] [50] although results have been conflicting. In a randomized, controlled, double-blind study of 44 patients with PH, sildenafil was associated with improvements in pulmonary pressure and vasomotility, RV function, left ventricular relaxation and distensibility, and lung interstitial water balance. 48 In contrast, among 216 patients with HFpEF without documented PH in the multicentre, double-blind, placebo-controlled, parallel-group, randomized PDE-5 Inhibition to Improve Clinical Status and Exercise Capacity in Heart Failure with Preserved Ejection Fraction (RELAX) trial, sildenafil did not improve exercise capacity or clinical status. 50 Finally, in 52
patients with mostly IpcPH due to HFpEF, sildenafil had no significant effects on haemodynamics and exercise capacity. 49 In all three trials, PDE-5 inhibition was well-tolerated. In aggregate, these data have not led to a recommendation for these drugs for HFpEF in recent ESC Guidelines. However, there remains the question of whether patients with CpcPH-HFpEF (and not IpcPH or all-comers with HFPEF) may be a subgroup in whom PDE-5 inhibition may be beneficial. Recent observational data from the European Prospective registry of newly initiated therapies in pulmonary hypertension (COMPERA) registry identified 226 patients with CpcPH-HFpEF who received medications approved for pulmonary arterial hypertension, predominantly (94%) PDE-5 inhibitors, and showed improvements in NYHA functional class, 6-minute walking distance, and plasma NT-proBNP after 3 and 12 months of therapy, although less pronounced than in patients with idiopathic pulmonary arterial hypertension. 38 There was no control population of untreated patients with CpcPH-HFpEF in COMPERA.
A new German trial of PDE-5 inhibition in patientS with heart failure with preServed ejection fractIon and cOmbined post-and precapillary pulmonary hypertension (PASSION) will test the hypothesis that treatment with tadalafil will reduce the combined outcome of HF hospitalization and all-cause mortality in patients with CpcPHHFpEF (www.DRGS.de German Registry for Clinical Studies DRKS00014595).
Other drugs that are used in PH without HF, such as endothelin antagonists and prostacyclin analogues, but also soluble guanylate cyclase (sGC) inhibitors like riociguat and vericiguat have shown potentially interesting results in smaller studies, but have not been proven to favourably affect outcome, 41 and are currently not recommended for HFpEF. Ongoing trials are testing the effect of endothelin receptor antagonist macitentan on NT-proBNP levels in patients with HFpEF and pulmonary vascular disease (SERENADE trial, NCT03153111) as well as the effect of prostacyclin analogue treprostinil on 6-minute walk distance in patients with HFPEF-PH (NCT03037580). One small invasive haemodynamic study has suggested that pulmonary vasoconstriction in patients with HFpEF may respond well to dobutamine infusion. 51 
Plasma volume expansion Mechanism
Plasma volume expansion has been suggested as the primary pathophysiologic mechanism in a subgroup of patients with HFpEF. 52 More recently, this mechanism has been demonstrated in obese patients with HFpEF (body mass index > _ 35 kg/m 2 ), in whom increases in pulmonary capillary wedge pressure correlated with plasma volume expansion. Volume expansion was associated with right heart dilatation and increased total heart volumes, resulting in increased pericardial restraint and enhanced ventricular interaction which contributed to raised left ventricular filling pressures. 53 Experimental models of percutaneous pericardial resection provided proof of concept regarding the role of pericardial restraint in HFpEF, by showing that pericardial resection mitigated elevation in left ventricular end-diastolic pressure in large animal models of HFpEF. 54 
Therapy
In the CHAMPION trial, reduction in HF hospitalizations was related to greater use of diuretics in the pulmonary artery pressure-guided treatment group, 32 where the vast majority (73.5%) of medication changes involved loop or thiazide diuretic dosing, resulting in an increase in daily dose of loop diuretics by 52.1 mg (furosemide equivalent) compared with only 0.4 mg in controls. This suggests that addressing volume overload via diuresis may be a fundamental component of the optimal management of HFpEF. While initially developed as anti-diabetic drugs, the sodiumglucose co-transporter-2 inhibitors (SGLT2i) have emerged as osmotic diuretics that may have utility in the treatment of HFpEF. The SGLT2i empagliflozin is currently being investigated in a Phase III randomized double-blind placebo-controlled trial for its safety and efficacy compared to placebo on top of guideline-directed medical therapy in patients with HFpEF (regardless of diabetes), with the primary endpoint of time to first event of adjudicated cardiovascular death or adjudicated HF hospitalization (EMPEROR-Preserved trial ClinicalTrials.gov NCT03057951). By reducing renal glucose reabsorption and increasing urinary glucose excretion, SGLT2i also cause natriuresis and diuresis. 55, 56 Furthermore, SGLT2i may cause beneficial cardiometabolic and renal effects. 57 The SGLT2i luseogliflozin has been shown to reduce epicardial fat volume in parallel with the improvement of systemic micro-inflammation and weight loss in Japanese patients with type 2 diabetes. 58 These beneficial effects make SGLT2i particularly attractive for obese HFpEF patients with volume overload and adipose inflammation.
Systemic microvascular inflammation Mechanism
Immune-inflammatory activation in chronic HF releases inflammatory mediators which further augment pro-inflammatory and profibrotic The D-HART2 trial was a randomized placebo-controlled blinded trial designed to confirm the effects of anakinra on exercise tolerance in HFpEF; however, recently presented results among 28 patients with stable HFpEF and C-reactive protein > 2 mg/L showed that anakinra 100 mg daily failed to improve peak oxygen consumption and the minute ventilation/carbon dioxide production slope at 12 weeks, despite a reduction in C-reactive protein and NT-proBNP levels, and an improvement in exercise time and quality of life. 87 Similarly, therapeutic trials aimed at the NO-cGMP pathway have not been conclusive. In the Nitrate's Effect on Activity Tolerance in Heart Failure with Preserved Ejection Fraction (NEAT-HFpEF) trial, 88 • Plasma levels of soluble interleukin-1 (IL-1) receptor-like 1, C-reactive protein, and growth differentiation factor 15 (GDF15) are high in HFpEF, [63] [64] [65] [66] and even higher in HFpEF than HFrEF. 65 ,66
• C-reactive protein correlated positively with left ventricular end-diastolic pressure, 67 and increased levels of inflammatory markers (e.g. C-reactive protein) were independently associated with asymptomatic diastolic dysfunction in patients with metabolic syndrome at risk of HFpEF. 68 • Comorbidities associated with HFpEF (e.g. hypertension, obesity, diabetes) and their induced inflammatory state [reflected by high circulating levels of interleukins and tumour necrosis factor (TNF)-a] were predictive of incident HFpEF, but not incident HFrEF.
69
• Two large cross-sectional studies, one in patients with acute dyspnoea and preserved ejection fraction 70 and one in patients with HFpEF, 71 demonstrated the correlation of soluble ST2 (member of the IL-1 receptor family) and pentraxin 3 with the presence of diastolic dysfunction and HFpEF, as well as their strong association with mortality.
• In acute HFpEF, changes in levels inflammatory markers (pentraxin-3, TNF-receptor1a, myeloperoxidase, and lymphotoxin beta receptor) were related to outcome in HFpEF, but not in HFrEF. 72 
Left ventricular biopsy evidence
• Left ventricular endomyocardial biopsy samples from patients with HFpEF showed increased expression of inflammatory endothelial adhesion molecules including VCAM1, high numbers of CD3, CD11, and CD45-positive leucocytes in the myocardium, increased inflammatory cell TGF-b expression, and increased levels of collagen I and III, providing convincing evidence that myocardial inflammation played an important role in HFpEF pathophysiology by promoting ECM changes and diastolic dysfunction. 73 • Endomyocardial biopsy data showed that HFpEF patients treated with statins, known to have anti-inflammatory effects, had less myocardial nitrotyrosine, higher myocardial PKG activity, less cardiomyocyte hypertrophy, and lower cardiomyocyte resting tension. • A 20-week caloric restriction diet in older, obese HFpEF patients significantly improved their symptoms, peak oxygen consumption (VO2), and quality of life scores, with the increase in peak VO2 strongly correlated with reduced body fat mass, increased percent lean body mass, higher thigh muscle/intermuscular fat ratio, and lower biomarkers of inflammation; thus supporting the hypothesis that overweight/obesity contributes to exercise intolerance in HFpEF through systemic inflammation. 79 • In an observational study, statin-treated HFpEF patients were less prone to develop atrial fibrillation. 80 Small Phase 2 trials and patients with HFpEF who received isosorbide mononitrate (120 mg daily) were less active and did not have better quality of life or submaximal exercise capacity than did patients who received placebo, contrary to hypothesis. Postulated reasons for these unexpected results include pharmacologic tolerance and pseudo-tolerance with high dose isosorbide mononitrate, since organic nitrates require bioactivation in the tissues, can chronically lower renal perfusion pressure leading to renal sodium retention, and may be associated with hypotension due to excessive preload reduction. Furthermore, organic nitrates such as isosorbide mononitrate have been paradoxically shown to cause endothelial dysfunction. In contrast, inorganic nitrites serve as important in vivo sources of NO in the presence of hypoxia and acidosis. An invasive haemodynamic study of 28 patients with HFpEF randomized to acute sodium nitrite infusion vs. placebo showed that exercise pulmonary capillary wedge pressure was reduced by nitrite infusion, associated with improvement of exercise cardiac output reserve. 89 Furthermore, inorganic nitrite was shown to abrogate arterial stiffening with exercise, thereby improving exercise haemodynamics in patients with HFpEF. 22 Chronic short-term
(1 week) dietary inorganic nitrate/nitrite therapy in the form of beetroot juice was shown to improve the primary outcome of submaximal aerobic endurance among elderly patients with HFpEF. 90 Longer
term inhaled nitrite therapy was tested in the Inorganic Nitrite Delivery to Improve Exercise Capacity in Heart Failure With Preserved Ejection Fraction (INDIE-HFpEF) trial-a multicentre, randomized, double-blind, placebo-controlled cross-over study assessing the effect of inhaled nebulized inorganic nitrite on peak exercise capacity in HFpEF. 91 However, recently reported results showed no improvement in the primary endpoint of peak oxygen consumption with inhaled nitrite therapy for 4 weeks, compared to placebo, and without effects on daily activity levels, NT-proBNP, or quality of life. 92 Nonetheless, in view of the wealth of data showing favourable effects in the inorganic nitrate/nitrite pathway, 89, [93] [94] [95] there is still intense interest in targeting this pathway in HFpEF, with multiple clinical trials underway (NCT02713126, NCT02918552, NCT03015402, NCT02980068, NCT02840799, NCT03289481). Targeting sGC to enhance cGMP has also been tested in the SOLuble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) trial, a Phase IIb study of the oral sGC stimulator vericiguat in patients with HFpEF. Although this trial did not demonstrate changes in its primary endpoints of NT-proBNP and left atrial volume at 12 weeks, 96 vericiguat was well-tolerated and, in exploratory analyses, patients randomized to the target dose of 10 mg of vericiguat experienced more pronounced improvement in healthrelated quality of life, physical limitations, NYHA class, and signs and symptoms of congestion. 97 These hypothesis-generating data require prospective validation in subsequent studies, and further studies to understand the mechanism of potential improvements in health status without NT-proBNP decrease at 12 weeks (such as systemic non-cardiac mechanisms).
Targeting particulate guanylate cyclase via stimulation with natriuretic peptides is another strategy to enhance cGMP. As neprilysin breaks down several vasoactive peptides, including the biologically active natriuretic peptides, administration of sacubitril/valsartan both blocks the renin-angiotensin system and augments the endogenous vasoactive peptide system. In a 301 patient Phase II trial in HFpEF, Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT), 98 sacubitril/valsartan reduced NT-proBNP at 12 weeks, and improved both left atrial function and NYHA class at 36 weeks. These findings were the basis for the Prospective Comparison of ARNI with ARB Global Outcomes in HF With Preserved Ejection Fraction (PARAGON-HF) trial, a fully recruited 4800 patient outcomes trial that will assess whether sacubitril/valsartan can reduce morbidity and mortality in HFpEF. 99 Finally, trials of PDE-5 inhibition (targeting breakdown of cGMP) in HFpEF have also produced mixed results, as discussed above.
Cardiometabolic abnormalities Mechanism
The failing heart is characterized by impaired myocardial energetics, and there is increasing interest in the role of energetic impairment in the development and progression of HFpEF. Several mechanisms underlie impaired myocardial energetics in HF ( Table 2) . Of note, most of these mechanistic data derive from studies in HFrEF and dilated cardiomyopathy, and direct evidence in HFpEF is limited. Important indirect data from skeletal muscles of older patients with HFpEF showed that skeletal muscle mitochondrial content, oxidative capacity, and fusion were abnormal in 20 older patients with HFpEF, compared to age-matched healthy controls, and these abnormalities were related to the extent of exercise intolerance in these patients. 106 Whether similar abnormalities exist in the myocardium of patients with HFpEF remains to be demonstrated and warrants investigation.
Therapy
Drugs that target cardiometabolic functional abnormalities are currently under investigation for the treatment of HFpEF. 102 Partial adenosine A1-agonists: capadenoson and neladenoson Preclinical studies have demonstrated that myocardial energy metabolism and utilization, as well as calcium homeostasis, are improved by the partial adenosine A1 receptor agonist capadenoson. Neladenoson bialanate is a highly potent and selective non-adenosine like partial adenosine A1 receptor agonist suitable for once daily oral use. Treatment of HFrEF patients with the novel partial adenosine A1 agonist neladenoson appeared to be safe in two small pilot studies, and no atrioventricular conduction disorders or neurological side effects were observed. 107 An ongoing double-blind, placebo-controlled phase II trial is currently exploring the effects of neladenoson in approximately 300 patients with chronic HF and preserved ejection fraction.
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Carnitine palmitoyltransferase-1 inhibitors: etomoxir and perhexiline The enzyme carnitine palmitoyltransferase-1 (CPT1) is involved in mitochondrial uptake of fatty acids and thereby switches energy metabolism from fatty acids to glucose oxidation. 104 Two CPT1 inhibitors, etomoxir and perhexiline, have been studied for the treatment of HF. Although etomoxir showed an improvement in left ventricular ejection fraction, cardiac output, and clinical status in HF, its development was halted due to unacceptably high liver transaminase levels in 109 The effects of perhexiline have been studied in a few small placebo-controlled clinical studies in patients with HFrEF and HFpEF. 110, 111 The majority of these studies showed an improvement in exercise capacity. However, larger trials are needed to confirm the beneficial effects of perhexiline for the treatment of HFpEF.
Fatty acid b-oxidation inhibitor: trimetazidine Trimetazidine directly inhibits fatty acid b-oxidation. 104 A few smaller clinical studies in HF showed improvements in systolic and diastolic function, quality of life, and exercise capacity. 112 A meta-analysis of 17 randomized controlled trials of trimetazidine in HF (involving 955 patients) showed improvement in left ventricular ejection fraction in patients with ischaemic and non-ischaemic HF. 113 However, data on trimetazidine in HF are largely confined to HFrEF, and studies in HFpEF are needed.
Mitochondrial enhancer: elamipretide Elamipretide is currently under investigation for the treatment of HFrEF and HFpEF. 114 Elamipretide binds to cardiolipin that increases the efficiency of mitochondrial respiration under conditions of oxidative stress, reducing the production of reactive oxygen species (ROS) and increasing ATP levels thereby normalizing mitochondrial function in affected cells and organs. 111 An ongoing double-blind, placebocontrolled Phase II study investigates the effects of elamipretide on diastolic pressure and function in 46 patients with HFpEF. 115 Intravenous iron: ferric carboxymaltose Iron deficiency is frequently found in patients with HFpEF and HFrEF.
In patients with advanced HF, iron content in the myocardium is reduced by 20-30%. 116 Iron deficiency directly impairs mitochondrial function since iron is a cofactor for haeme-containing enzymes and non-haeme iron-containing enzymes in the mitochondrial electron transport chain. Therefore, iron essential for generation of adenosine triphosphate (ATP) by oxidative phosphorylation of adenosine diphosphate (ADP). 117 Treatment of iron deficiency has consistently shown to improve symptoms and exercise capacity in patients with HFrEF. [118] [119] [120] The effects of intravenous iron in patients with HFpEF have been less well investigated. In an ongoing randomized, placebocontrolled trial, the effects of intravenous ferric carboxymaltose on 6-minute walking test (6-MWT) and symptoms are being tested in 200 patients with HFpEF and iron deficiency (https://clinicaltrials.gov/ ct2/show/NCT03074591).
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Cellular (titin)/extracellular (fibrosis, amyloid) structural abnormalities
Mechanism
The heart comprises a myocytic compartment and a non-myocytic compartment. Both compartments contribute to diastolic stiffness. 122, 123 Cardiomyocytes themselves from patients with HFpEF exhibit increased stiffness, while the extracellular matrix (ECM) expands and becomes of different compositions, also contributing to increased filling pressures. 124, 125 Furthermore, there is intense crosstalk between cardiomyocytes and non-cardiomyocytes, such that abnormalities in one compartment will usually be accompanied by changes in the other. 125 The (giant) elastic sarcomeric protein titin is the dominant regulator of myocardial passive tension, and thus of the cardiomyocytederived stiffness. Titin spans the sarcomere from the Z-disk to the M-band, functioning as a bidirectional elastic coil, that prevents the • The failing heart is characterized by abnormal mitochondrial structure and function (hyperplasia and reduced organelle size, poor organelle respiration, reduced mitochondrial membrane potential, and opening of membrane permeability pores). 100, 101 • There is impaired function of the electron transport chain, which powers extrusion of protons across the inner mitochondrial membrane and subsequently activates adenosine triphosphate (ATP) synthase, located on the inner mitochondrial membrane, which produces ATP through phosphorylation of adenosine diphosphate (ADP). 102 • As a result of mitochondrial changes in dilated cardiomyopathy, ATP synthesis is reduced and there is reduced energy supply in cardiomyocytes. 103 Both ventricular contraction and relaxation are energy-consuming processes in which ATP hydrolysis is required for myofilament detachment and subsequent myocardial relaxation and elasticity.
Change in substrate utilization
• Due to abnormal mitochondrial structure and function and impaired electron transport chain activity, the failing heart switches from fatty acid to glucose metabolism.
• Mitochondrial glucose oxidation is substantially decreased, which, together with an increase in glycolytic rates, results in a mismatch between glycolysis and glucose oxidation. 104 This mismatch causes an increase in lactate and proton production by the heart which leads to intracellular sodium and calcium overload, decreased cardiac efficiency and function. 104 Intracellular calcium overload
• Intracellular calcium overload is not only caused by a decrease in myocardial glucose oxidation but also by impaired function of the sarcoplasmic/endoplasmic reticulum Ca 2þ -ATPase (SERCA2a), which regulates cardiomyocyte contraction and relaxation by transporting Ca 2þ from the cytosol into the sarcoplasmic reticulum during diastole. 105 SERCA 2a deficiency and impaired calcium handling are associated with HF progression.
sarcomere from (late diastolic) overstretching, while enabling early diastolic recoil. Up to 80% of left ventricular passive stiffness may be explained by titin, especially when sarcomere lengths are still within physiological boundaries, while in (over-)stretched sarcomeres the contribution of the ECM becomes more dominant. 126 Titin regulates cardiomyocyte stiffness at the transcriptional and post-translational levels. At the transcriptional level, titin shifts from its compliant isoform N2BA toward its stiff isoform N2B have been postulated to contribute to diastolic dysfunction in HFpEF
127
; however, the N2BA/ N2B ratio was found to be similar between HFpEF and non-HF control patients undergoing coronary artery bypass grafting. 128 Instead, differences in titin phosphorylation were found between HFpEF and controls, associated with increased titin-dependent stiffness in patients with HFpEF. 128 48, 49 More recent data suggest that PDE-9 rather than PDE-5 may consistently increase cyclic GMP activity and alleviate cardiac hypertrophy and diastolic dysfunction. 134 Different molecular strategies may be useful to modulate the titin stiffness; for instance, genetic manipulation of an RNA motif leading to up-regulation of compliant titins, improvement in diastolic function, and enhanced exercise tolerance in a mouse model of HFpEF. 135 Clearly, this is an early study that will need to undergo multiple translational steps.
Extracellular matrix as a potential therapeutic target
Transforming growth factor-beta (TGF-b) is the master switch in fibrosis, and activation of G-coupled receptors such as angiotensin and endothelin receptors unequivocally leads to activation of TGF-b. 136 Pirfenidone inhibits TGF-b-induced fibrogenesis by blocking nuclear translocation of Smads, and has been shown to alleviate cardiac and renal fibrosis in a diabetic rat model, 137 fibrosis as an arrhythmogenic substrate in a dog model, 138 and fibrosis in mouse hearts subjected to pressure overload. 139 Pirfenidone is in clinical development for pulmonary fibrosis but also holds promise for cardiac fibrosis. 140 A trial in HFpEF with pirfenidone, the Efficacy and Safety of Pirfenidone in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction (PIROUETTE) trial, 141 is underway. Galectin-3 is a lectinbinding galactoside and has been shown to be upregulated in HFpEF. 142 Studies in mice deficient for galectin-3 have suggested that galectin-3 is not merely a bystander but a culprit for myocardial fibrosis, 143 and inhibition of galectin-3, achieved with binding carbohydrates, antisense RNA, or small designer molecules, have been shown to effectively reduce organ fibrosis. 144 Other potential antifibrotic targets are under study; however, the translational gap from laboratory studies onto clinical applicability is large given the very complex dynamics of fibrosis and its players.
Conclusion
While therapies proven to improve outcomes in HFpEF remain elusive to date, we have reviewed six potential mechanisms of potential translational significance. The first three haemodynamic mechanisms (left atrial hypertension, pulmonary hypertension, and volume overload) are currently being targeted with devices (interatrial septal device and PAP monitor) and existing (diuretics, RAAS blockers), as well as future (ARNI, SGLT2i), pharmacotherapies. The next three cellular/molecular mechanisms (microvascular inflammation, cardiometabolic abnormalities, and cellular/extracellular structural changes) represent great strides forward in our understanding of HFpEF and open the door to novel therapies including anti-inflammatory agents, mitochondrial activators, anti-fibrotic agents and strategies to enhance titin compliance. Several trials are underway that offer hope for future effective therapies. While results are eagerly awaited, the focus of clinical management should be on effective treatment of congestion, elimination of precipitating factors (e.g. uncontrolled blood pressure or atrial fibrillation), optimal management of inflammationinciting comorbidities, and identification of at-risk patients for preventive cardiovascular risk strategies.
